Lung cancer protein expression profiles of smokers and non-smokers

Cancer Genomics and Proteomics

Volumn 1, Issue 3, 2004, Pages 249-254

  Efferth, Thomas ^a   Koomägi, Reet ^b   Mattern, Jürgen ^b   Volm, Manfred ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Drug resistance; Hierarchical cluster analysis; Protein expression profiling; Smoking habits

Indexed keywords

EID: 43149104261     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Thun MJ, Henley SJ and Calle EE: Tobacco use and cancer: an epidemiological perspective for geneticists. Oncogene 21: 7307-7325, 2002.
2. Guerrero I and Pellicer A: Mutational activation of oncogenesis in animal model systems of carcinogenesis. Mutat Res 185: 293-308, 1987.
3. Reynolds SH, Anna CK, Brown KC, Wiest JS, Beattie EJ, Pero RW, Iglehart JD and Anderson MW: Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA 88: 1085-1089, 1991.
4. Wodrich W and Volm M: Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis 14: 1121-1124, 1993.
5. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications of human neoplasia. Am J Pathol 147: 545-560, 1995.
6. Carr IB: Pleiotropic drug resistance in hepatocytes induced by carcinogens administered to rats. Cancer Res 47: 5577-5583, 1987.
7. Cowan KH, Batist G, Tulpule A, Sinha BK and Myers CE: Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83: 9328-9332, 1986.
8. Michaud SE, Menard C, Guy LG, Gennaro G and Rivard A : Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1alpha/VEGF pathway. FASEB J 17: 1150-1152, 2003.
9. Carnevali S, Petruzzelli S, Longoni B, Vanacore R, Barale R, Cipollini M, Scatena F, Paggiaro P, Celi A and Giuntini C: Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 284: L955-L963, 2003.
10. Vayssier M, Banzet N, Francois D, Bellmann K and Polla BS: Tobacco smoke induces both apoptosis and necrosis in mammalian cells: differential effects of HSP70. Am J Physiol 275(4 Pt 1): L771-L779, 1998.
11. Xinarianos G, Scott FM, Liloglou T, Prime W, Callaghan J, Gosney JR and Field JK: Telomerase activity in non-small cell lung carcinomas correlates with smoking status. Int J Oncol 15: 961-965, 1999.
12. Shen H, Spitz MR, Qiao Y, Guo Z, Wang LE, Bosken CH, Amos CI and Wei Q : Smoking, DNA repair capacity and risk of non-small cell lung cancer. Int J Cancer 107: 84-88, 2003.
13. World Health Organization: Histological typing of lung tumors. Tumori 6: 253-272, 1981.
14. Carr DT and Mountain CF: Staging lung cancer. In: Lung Cancer. Chemical Diagnosis and Treatment (Straus MJ, ed). New York, Grune and Stratton, 1977, pp.151-161.
15. Mountain CF: A new international staging system for lung cancer. Chest 89 (Suppl): 225-233, 1986.
16. Volm M, Wayss K, Kaufmann M and Mattern J: Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15: 983-992, 1979.
17. Volm M, Drings P, Hahn EW and Mattern J: Prediction of the clinical chemotherapeutic response of the stage III lung adenocarcinoma patients by an in vitro short term test. Br J Cancer 57: 198-200, 1988.
18. Volm M, Koomägi R and Rittgen W: Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous cell lung carcinomas. Int J Cancer (Pred Oncol) 79: 294-299, 1998.
19. Volm M and Rittgen W: Cellular predictive factors for the drug response of lung cancer. Anticancer Res 20: 3449-3458, 2000.
20. Melzer MS: Paradox of carcinogens as cell destroyers and cell stimulators. A biochemical hypothesis. Eur J Cancer 16: 15-22, 1980.
21. Keyomarsi K and Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90: 1112-1126, 1993.
22. Sun Y: Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 8: 583-599, 1990.
23. Hayes JD and Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600, 1995.
24. Halinska A, Belej T and O'Brien PJ: Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts. Br J Cancer 27 Suppl: S23-27, 1996.
25. Laconi E, Pani and Farber E: The resistance phenotype in the development and treatment of cancer. Lancet Oncol 1: 235-241, 2000.
26. Solt DB and Farber E: A new principle for the analysis of chemical carcinogenesis. Nature 263: 702-703, 1976.
27. Hittelman WN: Clones and subclones in the lung cancer field. J Natl Cancer Inst 91: 1796-1799, 1999.
28. Volm M, Zerban H, Mattern J and Efferth T: Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine. Carcinogenesis 11: 169-172, 1990.
29. Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, Farber E and Cowan KH: Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 84: 7701-7705, 1987.
30. Morrow CS, Goldsmith ME and Cowan KH: Regulation of human glutathione S-transferase pi gene transcription: influence of 5'-flanking sequences and trans-activating factors which recognize AP-1-binding sites. Gene 88: 215-225, 1990.
31. Teeter LD, Eckersberg T, Tsai Y and Kuo MT: Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ 2: 429-437, 1991.
32. Choi KS, Bae MK, Jeong JW, Moon HE and Kim KW: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 36: 120-127, 2003.